CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

yahoo_finance
Original article

Agomab Announces Design of NOV-ERA Phase 2b Study with Ontunisertib in Fibrostenosing Crohn’s Disease

Phase 2OntunisertibNeutral
AI Analysis

Summary

Agomab announced the design of a Phase 2b study called NOV-ERA evaluating ontunisertib in fibrostenosing Crohn's disease.

Clinical Trial Data

Phase

2b

Importance:5/10
Sentiment:
0.00
clinical_trialphase_2bcrohns_diseasedrug_development
Related Companies

Read the original article

Published by yahoo_finance on June 23, 2026 8:05 PM

Read Original